Patients with advanced biliary tract cancers might benefit from first-line pembrolizumab combined with chemotherapy.

Published Date: 19 Apr 2023

Results from the phase III KEYNOTE-966 study showed that adding pembrolizumab (Keytruda) to gemcitabine and cisplatin increased overall survival in patients with untreated metastatic or unresectable biliary tract cancer.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

How access to specialized cancer centers affects glioblastoma outcomes

2.

Cancer Patients Who Completed Medication Survey Received More Help From Pharmacists

3.

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.

4.

U.S. Nurse Found Dead; Harvey Weinstein's Cancer; Creepy Source of Ear Pain

5.

Beyond What Is Visible in Myelofibrosis?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot